Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Consensus "Moderate Buy": Six analysts rate Tenax as a Moderate Buy (1 sell, 4 buy, 1 strong buy) with an average 12‑month price target of about $29.67.
• Q1 results beat estimates—Tenax reported ($0.38) EPS versus a consensus of ($1.26), a $0.88 beat—although analysts still model a full‑year loss of about -$2.58 per share.
• Company focus and ownership: Tenax is a clinical‑stage specialty pharma developing sustained‑release local anesthetics to extend analgesia and reduce opioid use, and hedge funds/institutions own only about 1.67% of the stock.

Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $29.6667.

Several equities analysts have recently weighed in on TENX shares. Cantor Fitzgerald started coverage on shares of Tenax Therapeutics in a research note on Tuesday, March 17th. They issued an "overweight" rating and a $35.00 price target on the stock. Lifesci Capital raised shares of Tenax Therapeutics to a "strong-buy" rating in a research note on Thursday, March 12th. William Blair reissued an "outperform" rating on shares of Tenax Therapeutics in a research note on Tuesday, March 10th. Finally, Guggenheim raised their price target on shares of Tenax Therapeutics from $25.00 to $34.00 and gave the stock a "buy" rating in a research note on Monday, March 16th.

Hedge Funds Weigh In On Tenax Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Letko Brosseau & Associates Inc. purchased a new position in shares of Tenax Therapeutics in the fourth quarter worth about $130,000. Virtu Financial LLC purchased a new position in Tenax Therapeutics during the third quarter worth about $92,000. Corient Private Wealth LLC purchased a new position in Tenax Therapeutics during the fourth quarter worth about $151,000. Quadrature Capital Ltd purchased a new position in Tenax Therapeutics during the fourth quarter worth about $252,000. Finally, Goldman Sachs Group Inc. purchased a new position in Tenax Therapeutics during the fourth quarter worth about $273,000. 1.67% of the stock is owned by hedge funds and other institutional investors.

Tenax Therapeutics Trading Down 2.5%

NASDAQ:TENX opened at $12.78 on Friday. The company's 50-day moving average price is $13.80 and its 200-day moving average price is $11.81. The company has a market cap of $219.82 million, a P/E ratio of -9.61 and a beta of 1.00. Tenax Therapeutics has a twelve month low of $5.34 and a twelve month high of $18.38.

Tenax Therapeutics (NASDAQ:TENX - Get Free Report) last posted its quarterly earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.88. On average, analysts expect that Tenax Therapeutics will post -2.58 earnings per share for the current year.

About Tenax Therapeutics

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company's proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax's lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.